Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., filed a Form 4 on September 1, 2026, reporting the sale of 16,666 shares of common stock executed pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 16,666 shares of Xeris Biopharma Holdings common stock disposed of on September 1, 2026.
  • Weighted average price: $8.4864 per share, with individual transactions ranging from $8.390 to $8.600, inclusive.
  • Remaining ownership: 1,127,796 shares of common stock beneficially owned directly following the reported transaction.
  • 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
  • Reporting person role: Beth Hecht is identified in the filing as Chief Legal Officer and Corporate Secretary.

Beth Hecht's Share Sale Details and Plan Background

According to the filing, Beth Hecht, serving as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), disposed of 16,666 shares of common stock on September 1, 2026, using transaction code "S." The filing notes the sale was carried out under a Rule 10b5-1 trading plan that Hecht adopted on August 8, 2025, more than a year before the reported transaction date.

The filing reports a weighted average sale price of $8.4864 per share. Because the shares were sold in multiple transactions, individual prices ranged from $8.390 to $8.600, inclusive, according to the disclosure. The filing states that Hecht "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."

Following the reported transaction, Hecht directly holds 1,127,796 shares of common stock, as reported in the filing. No derivative securities transactions were reported in Table II of the form. The filing was made by one reporting person and is not an amendment to a prior filing.

What Was Disclosed

The Form 4 discloses a single open-market sale of 16,666 common shares by Xeris Biopharma Holdings' Chief Legal Officer and Corporate Secretary on September 1, 2026, executed under a 10b5-1 plan adopted August 8, 2025, at a weighted average price of $8.4864.